OSR Holdings Inc

OSRH

Market cap $11.2M

BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China.

BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The extension provides the Company until August 31, 2026, to satisfy the rule by achieving a closing bid price of at least $1.00 per share for ten consecutive business days.

BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.

BELLEVUE, WA / ACCESS Newswire / January 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced the official closing of its acquisition of Woori IO, the reaffirmation of long-term equity alignment by Woori IO's historical shareholders, and the initiation of a strategic review regarding a potential combination of its medical device subsidiaries. Woori IO Acquisition Closed OSRH confirmed that the previously announced acquisition of Woori IO and the related share exchange transaction have been formally completed in Korea, effective January 26, 2026.

BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO).

BELLVUE, Wash., Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG confirming BCM Europe's interest in entering a global exclusive licensing transaction for VXM01, Vaximm's lead immunotherapy candidate.

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university BELLEVUE, Wash. , Dec. 19, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) ("OSR Holdings"), a global healthcare holding company, today announced that the shareholders of Woori IO Co., Ltd.

New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00, representing approximately 1,487% upside from the Company's December 3rd closing price of $0.63. The flash report highlights a major non-binding licensing term sheet announced by OSRH with BCM Europe AG (BCME) valued at $815 million for the global development and commercialization of VXM01, the Company's Phase 2b/3-ready oral T-cell immunotherapy program.

BELLEVUE, Wash. , Dec. 2, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG ("BCME").